messaggio

clik on the image and visit the new site

New site clik on the image

New site clik on the image

"In silico"


 From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
 Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Wednesday, 24 February 2010

Acinetobacter baumannii genomes





From NCBI site:

this is the complete list until now of Acinetobacter baumannii genomes :

A.baumannii AB0057 : 4050513 nt.

A. baumannii ATCC 17978: 3976747 nt.

A.baumannii AYE: 3936291 nt.

A.baumannii ACICU: 3904116 nt.

A.baumannii AB307-0294: 3760981 nt.

A.baumannii SDF : 3421954 nt.

I have compared two genomes each time and in descending order by MAUVE software:












Posted by Rodolfo Berretti at 23:08
Labels: